U.S. Markets close in 1 hr 13 mins

MediciNova, Inc. (MNOV)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
5.4218+0.1118 (+2.1055%)
As of 2:32PM EDT. Market open.
People also watch
CYTKOPXATTHILXRXGTXI

MediciNova, Inc.

4275 Executive Square
Suite 650
La Jolla, CA 92037
United States
858-373-1500
http://medicinova.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees10

Key Executives

NameTitlePayExercisedAge
Dr. Yuichi Iwaki M.D., Ph.D.Co-Founder, Chief Exec. Officer, Pres and Exec. Director800.46kN/A67
Mr. Ryan J. SelhornChief Financial Officer and Principal Accounting Officer58.75kN/A35
Mr. Masatsune OkajimaHead of Japanese Office and VP429kN/A49
Dr. Kazuko Matsuda M.D., Ph.D., MPHChief Medical Officer477.56kN/A51
Mr. Geoffrey G. O'Brien J.D., M.B.A.VP365.63k10.56k48
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company’s product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders, including primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction, including methamphetamine, opioid, and alcohol dependence. Its product pipeline also comprises MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, such as nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; MN-221 (bedoradrine), a ß2-adrenergic receptor agonist for the treatment of acute exacerbation of asthma; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.

Corporate Governance

MediciNova, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 7. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.